AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

EMA committee recommends approval of LINDIS Biotech’s Korjuny to treat malignant ascites MA in adults with EpCAM-positive carcinomas: Munich, Germany Wednesday, October 23, 2024 ...

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...

Siiltibcy compared favorably with other diagnostic products for detecting Mycobacterium tuberculosis infection.

BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

The European Medicines Agency has recommended Korjuny for the treatment of patients with intraperitoneal malignant ascites.

Accord Healthcare Limited (Accord) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

In the Netherlands, the Central Committee on Research Involving Human Subjects (CCMO) recently published a guideline to clarify the ...